Prucalopride

(Motegrity®)

Motegrity®

Drug updated on 11/16/2023

Dosage FormTablet (oral; 1 mg, 2 mg)
Drug ClassSerotonin-4 receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of chronic idiopathic constipation (CIC) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Motegrity (prucalopride) Prescribing Information.2020Takeda Pharmaceuticals America, Inc. Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines